PGEN PRECIGEN, INC.

NEUTRAL Impact: 3/10 Insider Cluster (4 insiders)
Horizon days Filed Jun 1, 2026 Processed 3d 23h ago
Insider cluster: 4 insiders, $1.0M total
Latest settled — T+1d
PGEN ▼ -1.30% at T+1d
NEUTRAL call ✗ call lost -1.30% · α vs SPY -0.60% · entry $3.86 → $3.81
Next anchor: T+5d in 3d
Currently $3.57 · -7.64% from $3.86 entry
Entry anchored
Jun 1, 03:59 PM ET
via Databento tick
T+1d
-1.30%
call -1.30% · α -0.60%
$3.81
settled 3d ago
T+5d
call — · α —
in 3d
T+20d
call — · α —
in 25d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Four top executives at Precigen (CEO, CFO, COO, CLO) sold a combined $1.02M in open-market sales on May 28, 2026, all at $4.36/share. This is a coordinated cluster sale by the entire C-suite, representing 0.07% of the $1.5B market cap — a trivial proportion. The simultaneous timing and identical price suggest a pre-arranged 10b5-1 plan or blackout-window opening, not a reaction to imminent news.

Key Financial Metrics

Direction
selling
Total Value
$1.0M
Insiders
4

Actionable Insight

The coordinated C-suite sale at identical price and date is characteristic of a pre-planned 10b5-1 trading plan or post-blackout window execution, not a bearish signal. Monitor for any 8-K filing or press release in the next 10 days that could explain the timing, but the dollar amount is too small to move the stock. The 30-day prior insider activity (5 sells, $1.1M) shows this is part of a routine pattern.

Key Facts

  • Four C-suite insiders sold on the same day (May 28, 2026) at the same price ($4.36).
  • Total open-market sales: $1.02M across 263,240 shares.
  • Sales represent only 0.07% of Precigen's $1.5B market cap.
  • CEO Helen Sabzevari sold the largest portion: $520K (119,250 shares).
  • No insider purchases were filed in the same window.

Financial Impact

Total insider sales of $1.02M, or 0.07% of market cap — immaterial relative to company size.

insider ownershipfloat

Risk Factors

  • If the sales were NOT under a 10b5-1 plan, the unanimity of C-suite selling could signal a shared bearish view on upcoming data or earnings.
  • Precigen is a clinical-stage biotech with binary pipeline catalysts — insider selling ahead of a data readout would be a red flag.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PGEN-1780345870355
4 reports for PGEN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PGEN — sortable, filterable
Type Now
Jun 1, 2026
3d ago
Insider Cluster
NEUTRAL ★ 3/10
$3.86 $3.81▼ −1.30%▼ −0.60%$3.57 (−7.64%)
Jun 1, 2026
3d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+1
May 13, 2026
22d ago
8-K
BULLISH ★ 7/10
$4.60 $4.60· 0.00%▼ −0.01%$3.57 (−22.50%)
Mar 30, 2026
9w ago
144
NEUTRAL ★ 3/10
$3.87 $3.93▲ +1.55%▲ +0.80%$3.57 (−7.88%)
Showing 4 of 4

US Market Status

Market Open — Closes in 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access